Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
This study investigated the tissue and serum concentrations of steroid hormones and the antiprogestogen RU 486 following mifepristone administration.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The present study was designed to examine the effect RU 486 administration on steroid hormone levels in serum and decidua. Sixty women at 6-7 weeks gestation were divided into three groups. The first group took a placebo 24 hours before interruption of pregnancy. The other two groups took 200 mg mifepristone 12 and 24 hours before the surgical procedure, respectively. The concentrations of steroids and mifepristone were measured by radioimmunoassay or high performance liquid chromatography. Mifepristone treatment increased the levels of estradiol, cortisol and testosterone in serum and decidual cytosol (p < 0.05 or p < 0.01). A minor elevation in progesterone level was observed but was not statistically significant. The tissue levels of progesterone, estradiol and testosterone were much higher than the serum levels, whereas RU 486 concentration in the tissue was only one-third of the serum level. In addition, the RU 486 level in decidual cytosol was of the same order as that of progesterone. This competitive concentration was not achieved in chorionic villi in our previous observation, explaining why mifepristone exerts its predominant effect on decidua rather than villi. It is concluded that RU 486 reached an effective inhibitory concentration in decidua and had significant effects on the endocrine milieu.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis 1991
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis 1991
Cited by (1)
References (44)
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis via crossref
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis via openalex
- doi:10.1210/jcem-68-2-270 via crossref
- doi:10.1016/0010-7824(89)90052-8 via crossref
- doi:10.1677/joe.0.1300071 via crossref
- doi:10.1055/s-0029-1211040 via crossref
- doi:10.1210/jcem-73-1-187 via crossref
- doi:10.1159/000293274 via crossref
- doi:10.1016/0002-9378(90)90784-5 via crossref
- doi:10.1016/s0015-0282(16)54002-3 via crossref
- doi:10.1210/jcem-71-6-1474 via crossref
- doi:10.1016/0010-7824(84)90014-3 via crossref
- doi:10.1093/oxfordjournals.humrep.a136554 via crossref
- doi:10.1159/000419646 via crossref
- doi:10.1093/oxfordjournals.humrep.a136338 via crossref
- doi:10.1016/s0140-6736(87)92988-6 via crossref
- W29948468 via openalex
- W174638640 via openalex
- W614906504 via openalex
- W1409257859 via openalex
- W1542467604 via openalex
- W1960008244 via openalex
- W1964022820 via openalex
- W1977338297 via openalex
- W1988853024 via openalex
- W1993693505 via openalex
- W2002110160 via openalex
- W2029540961 via openalex
- W2031572346 via openalex
- W2064035782 via openalex
- W2072175251 via openalex
- W2100655603 via openalex
- W2105820409 via openalex
- W2199876988 via openalex
- W2219628471 via openalex
- W2271398028 via openalex
- W2283048013 via openalex
- W2291477050 via openalex
- W2411884256 via openalex
- W6601170167 via openalex
- W6607096999 via openalex
- doi:10.1093/oxfordjournals.humrep.a137774 via crossref
- W6687816452 via openalex
- doi:10.1093/oxfordjournals.humrep.a138173 via crossref
Cited by (1)
Source provenance
- crossref
- last seen: 2026-06-07T01:00:42.099596+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-08-18T06:27:49.008893+00:00
License: CC0
· commercial use OK